Multinational Patterns of Second-line Antihyperglycaemic Drug Initiation Across Cardiovascular Risk Groups: Federated Pharmacoepidemiological Evaluation in LEGEND-T2DM

Lovedeep Singh Dhingra, MBBS

Arya Aminorroaya, MD, MPH

CarDS Lab, Yale School of Medicine

(for the LEGEND-T2DM investigators)

OHDSI

CarDS LAB

Background

Multinational Serial Cross-sectional Study 2011-2021

US National Databases

- IBM MarketScan®Commercial Claim and Encounters Data (CCAE)
- IBM Health MarketScan® Multistate Medicaid Database (Medicaid)
- IBM Health MarketScan® Medicare Supplemental and Coordination of Benefits Database (Medicare)
- Optum Clinformatics Extended Data Mart - Date of Death (Optum CEDM)
- Optum© de-identified Electronic Health Record Dataset (Optum EHR)
- US Open Claims

US Health System Databases

- Columbia University Irving Medical Center
- Johns Hopkins Medicine
- Stanford Medicine
- Department of Veterans Affairs Healthcare System

UK-IQVIA Medical Research Data (UK)

HIC, University of Dundee (Scotland)

Germany Disease Analyser (Germany)

Information System for Research in Primary Care (Spain)

France Longitudinal Patient Database (France)

Hong Kong Hospital Authority (Hong Kong)

Australia Longitudinal Patient Database (Australia)

# Multinational Serial Cross-sectional Study 2011-2021

Inclusion Criteria

- Age ≥18 years
- Presence of T2DM
- Prior metformin use
- No prior second-line anti-hyperglycemic agent use

Exposures

- Presence of established cardiovascular disease
- Calendar Years

4.6 million patients across 17 data sources

Outcomes

- Calendar-year trends for proportionate initiation 2nd line agents

- Comparison of annualized change in initiation of GLP-1 RA and SGLT2i in patients with and without CVD

Proportionate Incident Use of Second-line Anti-hyperglycemic Agents in 2021

- Across US databases, initiation of cardioprotective agents ranged from 35% at the VA health system to 68% at Columbia University.

- Across non-US databases, initiation of cardioprotective agents ranged from 15% in France to 55% in Scotland in 2021

GLP-1 RA Uptake
# in Patients with Established CVD

- Initiation of GLP-1 RAs increased to 20-25% across most US populations

- Initiation was <5% in the VA

- Initiation was low across non-US databases, reaching a maximum of 14% in France in 2021

SGLT2i Uptake
in Patients with Established CVD

- Initiation of SGLT2is increased to ~35% across US populations

- In the non-US databases, the initiation of SGLT2is was higher in most databases, reaching up to 54% in Scotland in 2021

- In France, the initiation was lower, reaching only to 6% in 2021

Slope Interaction for Annualized Change in Cardioprotective Agent Initiation in Patients with and without CVD (2016-2021)

Representative Examples for GLP-1 RA Initiation

Data Source	With-CVD Slope	Without-CVD Slope	P-Value
CCAE	0.019 (0.011 to 0.026)	0.068 (0.037 to 0.099)	0.003
Columbia	0.017 (0.011 to 0.023)	0.031 (0.016 to 0.047)	0.040
Medicare	0.051 (0.009 to 0.092)	0.051 (0 to 0.102)	0.986
France	0.003 (0.001 to 0.006)	0.014 (0.004 to 0.023)	0.024
Spain	0.003 (-0.001 to 0.006)	0.010 (0.001 to 0.019)	0.062

Representative Examples for SGLT2i Initiation

Data Source	With-CVD Slope	Without-CVD Slope	P-Value
CCAE	0.014 (0.006 to 0.023)	0.035 (0.011 to 0.059)	0.053
Columbia	0.037 (0.022 to 0.052)	0.024 (0.013 to 0.034)	0.074
Medicare	0.092 (0.011 to 0.172)	0.056 (0.008 to 0.104)	0.325
France	0.001 (-0.001 to 0.003)	0.005 (-0.001 to 0.011)	0.132
Spain	0.033 (0.016 to 0.049)	0.065 (0.017 to 0.112)	0.115

Conclusion

- LEGEND-T2DM is the <u>largest multinational pharmacoepidemiology study</u> of anti-hyperglycemic therapy.

- Despite increased uptake, there is <u>vast variation in use of cardioprotective</u> therapies uses across populations with CVD.

- The <u>uptake of these has been lower in the US</u>, relative to other countries, particularly in patients with established CVD.

- <u>Lack of selective use in CVD patients</u> despite specific benefit in the population.

Published in *BMJ Medicine*. 2023 Oct 6;2(1)

Thank you for your attention!

Co-investigators

- Rohan Khera
- Marc A Suchard
- Kelly Li
- Harlan M Krumholz
- George Hripcsak
- Jin Zhou
- Martijn J Schuemie
- Yuan Lu
- Anna Ostropolets
- RuiJun Chen
- Tara Anand
- Faaizah Arshad
- Seng Chan You
- Patrick B Ryan
- David A. Dorr
- Clair Blacketer
- Fan Bu
- Thomas Falconer
- Wallis CY Lau
- Yuntian Liu
- Paul Nagy

- Daniel R. Morales
- Talita Duarte-Salles
- Kenneth KC Man
- Evan Minty
- Mary Grace Bowring
- Michael Cook
- Nestoras Mathioudakis
- Akihiko Nishimura
- Carlen Reyes
- Andrea Pistillo
- Nicole Pratt
- Eric Yuk Fai Wan
- Jianxiao Yang
- Can Yin
- Sarah Seager
- Scott L DuVall
- Tina E French
- Elizabeth E Hanchrow
- Michael E Matheny
- Michael E McLemore
- Katherine R Simon

Correspondence to:

Rohan Khera, MD, MS
rohan.khera@yale.edu, @rohan_khera

Marc A Suchard, MD, PhD
msuchard@ucla.edu, @suchard_group